Drugs / HPB-092
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07137637 | Dec 2025 → Sep 2027 expected | acute myeloid leukemia | Hangzhou Polymed Biopharmaceuticals, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HPB-092 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07137637 ↗ |
| Action | Inhibit | “This novel small molecule selectively inhibits both FLT3 and interleukin-1 receptor-associated kinase 4 (IRAK4).” NCT07137637 ↗ |
| Modality | Small molecule | “This novel small molecule selectively inhibits both FLT3 and interleukin-1 receptor-associated kinase 4 (IRAK4).” NCT07137637 ↗ |
| Route | Oral | “HPB-092 is formulated as a tablet for oral administration, taken twice daily (BID) over consecutive 28-day cycles.” NCT07137637 ↗ |
| Target | FLT3 | “This novel small molecule selectively inhibits both FLT3 and interleukin-1 receptor-associated kinase 4 (IRAK4).” NCT07137637 ↗ |
| Target | IRAK4 | “This novel small molecule selectively inhibits both FLT3 and interleukin-1 receptor-associated kinase 4 (IRAK4).” NCT07137637 ↗ |